DK2130537T3 - N3-alkylerede benzimidazolderivater som MEK-inhibitorer - Google Patents
N3-alkylerede benzimidazolderivater som MEK-inhibitorerInfo
- Publication number
- DK2130537T3 DK2130537T3 DK09011389.5T DK09011389T DK2130537T3 DK 2130537 T3 DK2130537 T3 DK 2130537T3 DK 09011389 T DK09011389 T DK 09011389T DK 2130537 T3 DK2130537 T3 DK 2130537T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzimidazole derivatives
- mek inhibitors
- alkylated benzimidazole
- alkylated
- mek
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36400702P | 2002-03-13 | 2002-03-13 | |
EP03714148A EP1482932B1 (en) | 2002-03-13 | 2003-03-13 | N3 alkylated benzimidazole derivatives as mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2130537T3 true DK2130537T3 (da) | 2013-02-18 |
Family
ID=28041856
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10011691.2T DK2275102T3 (da) | 2002-03-13 | 2003-03-13 | N3-alkylerede benzimidazolderivater som mek-hæmmere |
DK09011389.5T DK2130537T3 (da) | 2002-03-13 | 2003-03-13 | N3-alkylerede benzimidazolderivater som MEK-inhibitorer |
DK03714148.8T DK1482932T3 (da) | 2002-03-13 | 2003-03-13 | N3-alkylerede benzimidazolderivater som MEK-inhibitorer |
DK15177189.6T DK3000810T3 (da) | 2002-03-13 | 2003-03-13 | N3-alkyleret benzimidazolderivat som mek-inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10011691.2T DK2275102T3 (da) | 2002-03-13 | 2003-03-13 | N3-alkylerede benzimidazolderivater som mek-hæmmere |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03714148.8T DK1482932T3 (da) | 2002-03-13 | 2003-03-13 | N3-alkylerede benzimidazolderivater som MEK-inhibitorer |
DK15177189.6T DK3000810T3 (da) | 2002-03-13 | 2003-03-13 | N3-alkyleret benzimidazolderivat som mek-inhibitor |
Country Status (35)
Country | Link |
---|---|
US (11) | US20030232869A1 (da) |
EP (5) | EP3000810B1 (da) |
JP (4) | JP4093966B2 (da) |
KR (3) | KR100984613B1 (da) |
CN (4) | CN100519539C (da) |
AR (3) | AR038971A1 (da) |
AT (1) | ATE449605T1 (da) |
AU (2) | AU2003218157C1 (da) |
BE (1) | BE2019C510I2 (da) |
BR (1) | BR122018007328B8 (da) |
CA (1) | CA2478374C (da) |
CL (2) | CL2012002380A1 (da) |
CY (3) | CY1109727T1 (da) |
DE (1) | DE60330227D1 (da) |
DK (4) | DK2275102T3 (da) |
DO (4) | DOP2003000613A (da) |
ES (5) | ES2335276T3 (da) |
HK (3) | HK1070823A1 (da) |
HU (2) | HUE025767T2 (da) |
IL (4) | IL163995A0 (da) |
IS (4) | IS2748B (da) |
LT (1) | LTC1482932I2 (da) |
LU (1) | LUC00100I2 (da) |
MX (1) | MXPA04008893A (da) |
NL (1) | NL300974I2 (da) |
NZ (1) | NZ535158A (da) |
PA (1) | PA8569301A1 (da) |
PL (5) | PL230179B1 (da) |
PT (4) | PT2130537E (da) |
SG (3) | SG194238A1 (da) |
SI (4) | SI2130537T1 (da) |
TW (3) | TWI338685B (da) |
UA (1) | UA77765C2 (da) |
WO (1) | WO2003077914A1 (da) |
ZA (1) | ZA200407220B (da) |
Families Citing this family (239)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2335276T3 (es) * | 2002-03-13 | 2010-03-24 | Array Biopharma, Inc. | Derivados de bencimidazol alquilado n3 como inhibidores de mek. |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US20060084682A1 (en) * | 2002-12-13 | 2006-04-20 | Heerding Dirk A | Thrombopoietin mimetics |
US20060140872A1 (en) * | 2003-02-26 | 2006-06-29 | Kowa Co., Ltd. | Novel signaling pathway for the production of inglammatory pain and neuropathy |
DE602004023207D1 (de) | 2003-07-24 | 2009-10-29 | Warner Lambert Co | Benzimidazol-derivate als mek-hemmer |
US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
TWI349664B (en) | 2003-09-22 | 2011-10-01 | S Bio Pte Ltd | Benzimidazole derivatives: preparation and pharmaceutical applications |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005051301A2 (en) * | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
BRPI0416852A (pt) * | 2003-11-21 | 2007-02-27 | Array Biopharma Inc | inibidores da quinase akt |
WO2005058341A2 (en) * | 2003-12-11 | 2005-06-30 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
AU2005298932B2 (en) | 2004-10-20 | 2012-03-22 | Merck Serono Sa | 3-arylamino pyridine derivatives |
EP1828184B1 (en) * | 2004-12-01 | 2009-09-16 | Merck Serono SA | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
CN101626767A (zh) | 2005-05-18 | 2010-01-13 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
ES2715044T3 (es) * | 2005-06-23 | 2019-05-31 | Array Biopharma Inc | Procedimiento de SNAr para la preparación de compuestos de benzimidazol |
CA2612419C (en) * | 2005-06-23 | 2017-06-13 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
AU2012261703B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
AU2013203939B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
DK1934174T3 (da) * | 2005-10-07 | 2011-08-01 | Exelixis Inc | Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme |
US7968108B2 (en) * | 2005-10-25 | 2011-06-28 | Metbro Distributing L.P. | Hydrogen cyanamide pesticide formulations |
US7572460B2 (en) * | 2005-10-25 | 2009-08-11 | Rodrigo Rodriguez-Kabana | Hydrogen cyanamide pesticide formulations |
US20090030058A1 (en) * | 2005-12-21 | 2009-01-29 | Mohammed Pervez | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
CA2534243A1 (fr) | 2006-01-25 | 2007-07-25 | Hydro Quebec | Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
MX2008013097A (es) * | 2006-04-18 | 2008-10-27 | Ardea Biosciences Inc | Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona. |
BRPI0713555A2 (pt) | 2006-07-06 | 2012-03-20 | Array Biopharma, Inc. | ciclopenta [d] pirimidinas como inibidores de akt protéina cinase |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
JP5231410B2 (ja) | 2006-07-06 | 2013-07-10 | アレイ バイオファーマ、インコーポレイテッド | Aktプロテインキナーゼ阻害剤としてのジヒドロフロピリミジン |
US9303040B2 (en) | 2006-07-06 | 2016-04-05 | Array Biopharma Inc. | Substituted piperazines as AKT inhibitors |
US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
CN101583616B (zh) * | 2006-08-21 | 2012-05-30 | 健泰科生物技术公司 | 氮杂苯并噻吩基化合物及使用方法 |
WO2008024725A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
BRPI0714629A2 (pt) | 2006-08-21 | 2013-05-07 | Genentech Inc | composto, composiÇço farmacÊutica, mÉtodo para inibir o crescimento celular, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para trataruma doenÇa auto-imune, lesço àsseo destrutiva, distérbios proliferativos, doenÇas infecciosas, doenÇas virais, doenÇas fibràticas ou doenÇas neurodegenerativas |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
WO2008125820A1 (en) * | 2007-04-13 | 2008-10-23 | Astrazeneca Ab | Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii |
US8509487B2 (en) * | 2007-04-19 | 2013-08-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for optically measuring a parameter of an object |
WO2008157179A2 (en) | 2007-06-12 | 2008-12-24 | Genentech, Inc. | N-substituted azaindoles and methods of use |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
JP5542282B2 (ja) * | 2007-07-05 | 2014-07-09 | アレイ バイオファーマ、インコーポレイテッド | Aktプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン |
US8618097B2 (en) | 2007-07-05 | 2013-12-31 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
AU2008313504A1 (en) * | 2007-10-15 | 2009-04-23 | Astrazeneca Ab | Combination 059 |
EP2227469B9 (en) | 2007-11-12 | 2014-09-10 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
CN101945870B (zh) | 2007-12-19 | 2012-10-03 | 健泰科生物技术公司 | 5-苯氨基咪唑并吡啶和使用方法 |
CA2704125A1 (en) | 2007-12-19 | 2009-07-09 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
JP2011506533A (ja) | 2007-12-20 | 2011-03-03 | エフ.ホフマン−ラ ロシュ アーゲー | Mekキナーゼ阻害剤としての置換ヒダントイン |
US8486963B2 (en) | 2007-12-21 | 2013-07-16 | Genentech, Inc. | Azaindolizines and methods of use |
ES2401685T3 (es) * | 2008-01-09 | 2013-04-23 | Array Biopharma, Inc. | Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT |
US8835434B2 (en) | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
EP2240494B1 (en) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Thieno-pyridine derivatives as mek inhibitors |
SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
JP5404622B2 (ja) | 2008-06-23 | 2014-02-05 | パナソニック株式会社 | 無線通信基地局装置および参照信号割当方法 |
MX2010014559A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Heterociclos bicíclicos sustituidos y metodos de uso. |
US8492427B2 (en) * | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
SI2307376T1 (sl) | 2008-08-04 | 2016-02-29 | Merck Patent Gmbh | Nove spojine fenilamino izonikotinamida |
CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资(香港)有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
WO2010051245A1 (en) * | 2008-11-03 | 2010-05-06 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
JP2013508318A (ja) | 2009-10-21 | 2013-03-07 | バイエル・ファルマ・アクチェンゲゼルシャフト | 置換されたベンゾスルホンアミド誘導体 |
EP2491016A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
CN102574782B (zh) | 2009-10-21 | 2014-10-08 | 拜耳知识产权有限责任公司 | 取代的卤代苯氧基苯甲酰胺衍生物 |
WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
KR20140117684A (ko) | 2010-06-25 | 2014-10-07 | 노파르티스 아게 | 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물 |
CN103221043B (zh) | 2010-08-05 | 2016-04-06 | 卡斯西部储备大学 | 用于治疗神经元连接发育障碍的erk抑制剂 |
EP2624696B1 (en) | 2010-10-06 | 2016-12-21 | Glaxosmithkline LLC | Benzimidazole derivatives as pi3 kinase inhibitors |
CA2816188A1 (en) | 2010-10-29 | 2012-05-03 | Marion Hitchcock | Substituted phenoxypyridines |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
EP2694073B1 (en) | 2011-04-01 | 2018-08-08 | Genentech, Inc. | Combinations of akt and mek inhibitors for treating cancer |
TR201802093T4 (tr) | 2011-04-01 | 2018-03-21 | Genentech Inc | Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu. |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
EP2714039A1 (en) * | 2011-05-23 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
EP2714037B1 (en) | 2011-05-25 | 2016-07-13 | Université Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
WO2013066483A1 (en) | 2011-08-31 | 2013-05-10 | Novartis Ag | Synergistic combinations of pi3k- and mek-inhibitors |
CN103764134A (zh) | 2011-09-01 | 2014-04-30 | 诺华股份有限公司 | 有机化合物用于治疗努南综合征的用途 |
EP2570127A1 (en) | 2011-09-16 | 2013-03-20 | Sanofi | Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors |
SG11201401460PA (en) | 2011-10-14 | 2014-09-26 | Array Biopharma Inc | POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とhsp90阻害剤の組合せ療法 |
EP2773345A1 (en) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
EP2797957B1 (en) | 2011-11-23 | 2019-06-19 | MedImmune, LLC | Binding molecules specific for her3 and uses thereof |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
BR112014016870A2 (pt) | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
CN103204825B (zh) | 2012-01-17 | 2015-03-04 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途 |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
RU2677245C2 (ru) * | 2012-03-20 | 2019-01-16 | Новартис Аг | Комплексная терапия |
EP2836873B1 (en) | 2012-04-09 | 2020-03-11 | Switch Materials, Inc. | Switching materials, and compositions and methods for making same |
EP2856222A4 (en) | 2012-05-29 | 2016-01-27 | Switch Materials Inc | OPTICAL FILTER COMPRISING A VARIABLE TRANSMITTANCE LAYER |
WO2013178581A1 (en) | 2012-05-31 | 2013-12-05 | Bayer Pharma Aktiengesellschaft | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
AU2013304021B2 (en) | 2012-08-17 | 2016-09-15 | F. Hoffmann-La Roche Ag | Combination therapies for melanoma comprising administering cobimetinib and vermurafenib |
PL2903968T3 (pl) | 2012-10-02 | 2017-05-31 | Gilead Sciences, Inc. | Inhibitory demetylaz histonowych |
PL2909188T3 (pl) | 2012-10-12 | 2018-08-31 | Exelixis, Inc. | Nowy sposób wytwarzania związków do stosowania w leczeniu raka |
US9394257B2 (en) | 2012-10-16 | 2016-07-19 | Tolero Pharmaceuticals, Inc. | PKM2 modulators and methods for their use |
AR099630A1 (es) * | 2012-10-19 | 2016-08-10 | Novartis Ag | Preparación de un inhibidor de mek y formulación que lo comprende |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
JP6437444B2 (ja) * | 2012-11-29 | 2018-12-12 | ノバルティス アーゲー | 医薬的組合せ |
ES2676177T3 (es) | 2012-12-20 | 2018-07-17 | Novartis Ag | Una combinación farmacéutica que comprende binimetinib |
EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
AU2014218807A1 (en) | 2013-02-22 | 2015-09-03 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
ES2703208T3 (es) | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
WO2014131777A1 (en) | 2013-02-27 | 2014-09-04 | Epitherapeutics Aps | Inhibitors of histone demethylases |
EP2970205B1 (en) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
MY181085A (en) | 2013-03-21 | 2020-12-17 | Novartis Ag | Combination therapy |
AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
CA2933604A1 (en) | 2013-12-19 | 2015-06-25 | Actelion Pharmaceuticals Ltd | Antibacterial 1h-indazole and 1h-indole derivatives |
CN104788365B (zh) * | 2014-01-16 | 2018-08-10 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN106414721A (zh) | 2014-03-04 | 2017-02-15 | 菲特治疗公司 | 改良的重编程方法和细胞培养平台 |
AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
PT3116909T (pt) | 2014-03-14 | 2020-01-30 | Novartis Ag | Moléculas de anticorpos para lag-3 e suas utilizações |
EP3126345A1 (en) | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
US20170107486A1 (en) | 2014-04-21 | 2017-04-20 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
SG11201609286VA (en) | 2014-05-16 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Antibacterial quinazoline-4(3h)-one derivatives |
US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
CA2954508A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
WO2016040880A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
BR112017006664A2 (pt) | 2014-10-03 | 2017-12-26 | Novartis Ag | terapias de combinação |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
TN2017000129A1 (en) | 2014-10-14 | 2018-10-19 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-l1 and uses thereof |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
ME03385B (me) | 2014-12-23 | 2020-01-20 | Novartis Ag | Triazolopirimidin jedinjenja i njihova upotreba |
CA2974381A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
JP2016155776A (ja) * | 2015-02-24 | 2016-09-01 | 学校法人兵庫医科大学 | 抗腫瘍効果増強剤および抗腫瘍剤 |
CN107530415A (zh) | 2015-03-10 | 2018-01-02 | 艾杜罗生物科技公司 | 用于活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
EP3274344B1 (en) | 2015-03-25 | 2019-04-24 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
AR105646A1 (es) | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
RU2020142739A (ru) | 2015-08-28 | 2021-01-15 | Новартис Аг | Ингибиторы mdm2 и их комбинации |
AR105889A1 (es) | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos |
CA3001917A1 (en) | 2015-10-16 | 2017-04-20 | Fate Therapeutics, Inc. | Platform for the induction & maintenance of ground state pluripotency |
MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
PT3371314T (pt) | 2015-11-04 | 2023-08-31 | Fate Therapeutics Inc | Modificação genómica de células pluripotentes |
SG11201803145RA (en) | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
US11413309B2 (en) | 2016-01-20 | 2022-08-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US11096964B2 (en) | 2016-01-20 | 2021-08-24 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
WO2017210538A1 (en) | 2016-06-03 | 2017-12-07 | Giordano Caponigro | Pharmaceutical combinations |
US11091489B2 (en) | 2016-06-20 | 2021-08-17 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
US10689378B2 (en) | 2016-06-20 | 2020-06-23 | Novartis Ag | Triazolopyridine compounds and uses thereof |
CN109790166A (zh) | 2016-06-20 | 2019-05-21 | 诺华股份有限公司 | 咪唑并吡啶化合物用于治疗癌症 |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
WO2018065924A1 (en) * | 2016-10-04 | 2018-04-12 | Sun Pharmaceutical Industries Limited | Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation |
WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
CN108084078B (zh) * | 2016-11-24 | 2021-07-30 | 中山大学 | 一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法 |
EP3548049A4 (en) | 2016-12-05 | 2020-07-22 | Fate Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR IMMUNELL CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
EP3372624A1 (en) | 2017-03-06 | 2018-09-12 | Henkel AG & Co. KGaA | One component composition based on compounds with at least two exo-vinylene cyclic carbonate units |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2019096112A1 (zh) * | 2017-11-14 | 2019-05-23 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的苯并咪唑化合物及包含该化合物的组合物 |
CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
EP3769765B1 (en) | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
JP2021524835A (ja) | 2018-04-05 | 2021-09-16 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Axlキナーゼ阻害剤およびその使用 |
KR20210015902A (ko) | 2018-05-24 | 2021-02-10 | 얀센 바이오테크 인코포레이티드 | Psma 결합제 및 이의 용도 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
AU2018433575B2 (en) | 2018-07-25 | 2022-07-07 | Advanced Accelerator Applications Sa | Stable, concentrated radionuclide complex solutions |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
FI3837256T3 (fi) | 2018-08-17 | 2023-05-15 | Novartis Ag | Ureayhdisteitä ja koostumuksia smarca2/brm-atpaasiestäjinä |
CN112867512A (zh) | 2018-09-25 | 2021-05-28 | 意大利国际先进加速器应用有限公司 | 联合疗法 |
WO2020106306A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
SG11202106635WA (en) | 2018-12-21 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and kinase inhibitor |
JP2022520361A (ja) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
JP2022519923A (ja) | 2019-03-22 | 2022-03-25 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法 |
WO2020212832A1 (en) * | 2019-04-16 | 2020-10-22 | Alembic Pharmaceuticals Limited | Process of preparation of benzimidazole compounds |
MX2021012767A (es) | 2019-04-19 | 2021-11-18 | Janssen Biotech Inc | Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3. |
TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療braf相關的疾病和失調症之化合物 |
MX2022000164A (es) | 2019-07-03 | 2022-04-01 | Sumitomo Pharma Oncology Inc | Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos. |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021116901A1 (en) * | 2019-12-09 | 2021-06-17 | Biocon Limited | Forms of binimetinib and process for preparation thereof |
CN115052662A (zh) | 2019-12-20 | 2022-09-13 | 诺华股份有限公司 | 抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4122925A4 (en) * | 2020-03-17 | 2024-04-17 | Medshine Discovery Inc | PROTEOLYSIS REGULATOR AND METHOD OF USE |
WO2021206167A1 (ja) | 2020-04-10 | 2021-10-14 | 大鵬薬品工業株式会社 | 3,5-二置換ベンゼンアルキニル化合物とmek阻害剤とを用いた癌治療法 |
AU2021289163A1 (en) | 2020-06-09 | 2022-12-22 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders |
EP4168007A1 (en) | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
MX2023003867A (es) | 2020-10-05 | 2023-04-18 | Pf Medicament | Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii. |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
CN112759552A (zh) * | 2020-12-31 | 2021-05-07 | 武汉九州钰民医药科技有限公司 | 司美替尼的合成方法 |
CN112679438A (zh) * | 2020-12-31 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | 制备司美替尼的方法 |
CA3205523A1 (en) * | 2021-01-21 | 2022-07-28 | Michael Houghton | Processes for preparing pyrrolopyridine-aniline compounds |
EP4284838A2 (en) | 2021-01-28 | 2023-12-06 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
CA3206906A1 (en) | 2021-02-02 | 2022-08-11 | Andras Herner | Selective bcl-xl protac compounds and methods of use |
EP4308935A1 (en) | 2021-03-18 | 2024-01-24 | Novartis AG | Biomarkers for cancer and methods of use thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
EP4322953A1 (en) * | 2021-04-15 | 2024-02-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a pkc inhibitor and a mek inhibitor |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
EP4351577A1 (en) | 2021-06-09 | 2024-04-17 | F. Hoffmann-La Roche AG | Combination therapy for cancer treatment |
CN115490640A (zh) * | 2021-06-17 | 2022-12-20 | 深圳市塔吉瑞生物医药有限公司 | 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途 |
WO2023283425A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
AU2022383040A1 (en) | 2021-11-04 | 2024-03-07 | F. Hoffmann-La Roche Ag | Novel use of quinazolinone compound for the treatment of cancer |
WO2023084489A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023238000A1 (en) * | 2022-06-06 | 2023-12-14 | Glenmark Life Sciences Limited | Process for preparation of selumetinib and salts thereof |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1980001113A1 (en) | 1978-11-20 | 1980-05-29 | Braun Ag | Time-keeper in particular quartz controlled clock |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5250554A (en) | 1989-10-24 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives useful as angiotensin II inhibitors |
IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
US5218356A (en) * | 1991-05-31 | 1993-06-08 | Guenther Knapp | Wireless indoor data relay system |
US5216003A (en) | 1992-01-02 | 1993-06-01 | G. D. Searle & Co. | Diacid-containing benzimidazole compounds for treatment of neurotoxic injury |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5750545A (en) | 1993-07-23 | 1998-05-12 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
IL113472A0 (en) | 1994-04-29 | 1995-07-31 | Lilly Co Eli | Non-peptidyl tachykinin receptor antogonists |
US5520187A (en) | 1994-11-25 | 1996-05-28 | General Electric Company | Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts |
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
MX9708026A (es) | 1995-04-20 | 1997-11-29 | Pfizer | Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos. |
US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
GB9600344D0 (en) | 1996-01-09 | 1996-03-13 | Lilly Co Eli | Benzimidzolyl neuropeptide y receptor antagonists |
EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
EA199900139A1 (ru) | 1996-08-23 | 1999-08-26 | Пфайзер, Инк. | Производные арилсульфониламиногидроксамовой кислоты |
ATE272640T1 (de) | 1997-01-06 | 2004-08-15 | Pfizer | Cyclische sulfonderivate |
JP3765584B2 (ja) | 1997-02-03 | 2006-04-12 | ファイザー・プロダクツ・インク | アリールスルホニルアミノヒドロキサム酸誘導体 |
BR9807824A (pt) | 1997-02-07 | 2000-03-08 | Pfizer | Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz |
IL131123A0 (en) | 1997-02-11 | 2001-01-28 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6506798B1 (en) * | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
BR9810385A (pt) | 1997-07-01 | 2000-09-05 | Warner Lambert Co | Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek |
AU757046B2 (en) | 1997-07-01 | 2003-01-30 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
US6821963B2 (en) * | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
US6534503B1 (en) | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
AU2203800A (en) | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Antiviral method using mek inhibitors |
EP1140062B1 (en) | 1999-01-07 | 2005-04-06 | Warner-Lambert Company LLC | Treatment of asthma with mek inhibitors |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
AU2483400A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | 4'heteroaryl diarylamines |
JP2000204077A (ja) | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
JP2002534515A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 1−複素環置換されたジアリールアミン |
DE69928286T2 (de) | 1999-01-13 | 2006-07-13 | Warner-Lambert Co. Llc | Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren |
ID30439A (id) * | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
EP1144372B1 (en) | 1999-01-13 | 2005-11-30 | Warner-Lambert Company Llc | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
IL147617A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
IL147618A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
AU6068600A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
JP2003504400A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Mek阻害剤を用いた慢性痛の治療方法 |
EP1214330A1 (en) | 1999-09-21 | 2002-06-19 | LION Bioscience AG | Benzimidazole derivatives and combinatorial libraries thereof |
EP1339702A1 (en) | 2000-03-15 | 2003-09-03 | Warner-Lambert Company | 5-amide substituted diarylamines as mek inhibitors |
MXPA02008103A (es) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
EP1301472B1 (en) | 2000-07-19 | 2014-03-26 | Warner-Lambert Company LLC | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
YU14303A (sh) | 2000-08-25 | 2006-08-17 | Warner Lambert Company Llc. | Postupak pripremanja n-aril antranilnih kiselina i njihovih derivata |
AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
WO2002046168A1 (en) | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
JP4544820B2 (ja) | 2001-03-09 | 2010-09-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 複素環化合物 |
US20040039208A1 (en) | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
US6740649B2 (en) | 2001-09-17 | 2004-05-25 | Bristol-Myers Squibb Company | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE) |
WO2003054180A1 (en) | 2001-12-21 | 2003-07-03 | Warner-Lambert Company Llc | Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof |
CA2473545A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
AR038972A1 (es) * | 2002-03-13 | 2005-02-02 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilado como inhibidores de mek |
ES2335276T3 (es) | 2002-03-13 | 2010-03-24 | Array Biopharma, Inc. | Derivados de bencimidazol alquilado n3 como inhibidores de mek. |
DE10238002A1 (de) | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | Benzimidazolderivate |
CA2497827A1 (en) | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
US20040127395A1 (en) | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
DE602004023207D1 (de) | 2003-07-24 | 2009-10-29 | Warner Lambert Co | Benzimidazol-derivate als mek-hemmer |
DE102005032379A1 (de) | 2005-07-08 | 2007-01-11 | Conti Temic Microelectronic Gmbh | Zugangskontrollsystem für ein Kraftfahrzeug |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
ES2676177T3 (es) | 2012-12-20 | 2018-07-17 | Novartis Ag | Una combinación farmacéutica que comprende binimetinib |
-
2003
- 2003-03-13 ES ES03714148T patent/ES2335276T3/es not_active Expired - Lifetime
- 2003-03-13 CN CNB038107546A patent/CN100519539C/zh not_active Expired - Lifetime
- 2003-03-13 CN CN200910149291XA patent/CN101633645B/zh not_active Expired - Lifetime
- 2003-03-13 SI SI200332221T patent/SI2130537T1/sl unknown
- 2003-03-13 DK DK10011691.2T patent/DK2275102T3/da active
- 2003-03-13 PL PL377628A patent/PL230179B1/pl unknown
- 2003-03-13 SI SI200331731T patent/SI1482932T1/sl unknown
- 2003-03-13 MX MXPA04008893A patent/MXPA04008893A/es active IP Right Grant
- 2003-03-13 AT AT03714148T patent/ATE449605T1/de active
- 2003-03-13 ES ES10011691.2T patent/ES2549159T3/es not_active Expired - Lifetime
- 2003-03-13 EP EP15177189.6A patent/EP3000810B1/en not_active Revoked
- 2003-03-13 PA PA20038569301A patent/PA8569301A1/es unknown
- 2003-03-13 CN CN2008101903429A patent/CN101486682B/zh not_active Expired - Lifetime
- 2003-03-13 PT PT90113895T patent/PT2130537E/pt unknown
- 2003-03-13 SG SG2011042850A patent/SG194238A1/en unknown
- 2003-03-13 CA CA002478374A patent/CA2478374C/en not_active Expired - Lifetime
- 2003-03-13 PT PT03714148T patent/PT1482932E/pt unknown
- 2003-03-13 ES ES09011388T patent/ES2407849T3/es not_active Expired - Lifetime
- 2003-03-13 KR KR1020107007537A patent/KR100984613B1/ko active Protection Beyond IP Right Term
- 2003-03-13 EP EP10011691.2A patent/EP2275102B1/en not_active Expired - Lifetime
- 2003-03-13 PL PL401637A patent/PL401637A1/pl unknown
- 2003-03-13 DO DO2003000613A patent/DOP2003000613A/es unknown
- 2003-03-13 SG SG200608672-2A patent/SG148857A1/en unknown
- 2003-03-13 SI SI200332449T patent/SI2275102T1/sl unknown
- 2003-03-13 SI SI200332546T patent/SI3000810T1/sl unknown
- 2003-03-13 TW TW092105718A patent/TWI338685B/zh not_active IP Right Cessation
- 2003-03-13 SG SG2013013339A patent/SG2013013339A/en unknown
- 2003-03-13 ES ES15177189.6T patent/ES2635666T3/es not_active Expired - Lifetime
- 2003-03-13 TW TW099113379A patent/TWI343377B/zh not_active IP Right Cessation
- 2003-03-13 DK DK09011389.5T patent/DK2130537T3/da active
- 2003-03-13 DE DE60330227T patent/DE60330227D1/de not_active Expired - Lifetime
- 2003-03-13 UA UA20040907722A patent/UA77765C2/uk unknown
- 2003-03-13 ZA ZA200407220A patent/ZA200407220B/xx unknown
- 2003-03-13 EP EP09011388.7A patent/EP2130536B1/en not_active Expired - Lifetime
- 2003-03-13 PL PL401635A patent/PL233177B1/pl unknown
- 2003-03-13 EP EP09011389A patent/EP2130537B1/en not_active Expired - Lifetime
- 2003-03-13 JP JP2003575967A patent/JP4093966B2/ja not_active Expired - Lifetime
- 2003-03-13 PL PL401636A patent/PL233493B1/pl unknown
- 2003-03-13 DK DK03714148.8T patent/DK1482932T3/da active
- 2003-03-13 TW TW099113360A patent/TWI350285B/zh not_active IP Right Cessation
- 2003-03-13 WO PCT/US2003/007864 patent/WO2003077914A1/en active Application Filing
- 2003-03-13 DK DK15177189.6T patent/DK3000810T3/da active
- 2003-03-13 EP EP03714148A patent/EP1482932B1/en not_active Expired - Lifetime
- 2003-03-13 IL IL16399503A patent/IL163995A0/xx unknown
- 2003-03-13 NZ NZ535158A patent/NZ535158A/en not_active IP Right Cessation
- 2003-03-13 KR KR1020107007539A patent/KR100984573B1/ko active IP Right Grant
- 2003-03-13 PT PT100116912T patent/PT2275102E/pt unknown
- 2003-03-13 AR ARP030100887A patent/AR038971A1/es active IP Right Grant
- 2003-03-13 AU AU2003218157A patent/AU2003218157C1/en active Active
- 2003-03-13 HU HUE10011691A patent/HUE025767T2/en unknown
- 2003-03-13 KR KR1020047014182A patent/KR100984595B1/ko active IP Right Grant
- 2003-03-13 PT PT151771896T patent/PT3000810T/pt unknown
- 2003-03-13 ES ES09011389T patent/ES2394347T3/es not_active Expired - Lifetime
- 2003-03-13 PL PL401638A patent/PL401638A1/pl unknown
- 2003-03-13 US US10/387,879 patent/US20030232869A1/en not_active Abandoned
- 2003-03-13 CN CN2009101492905A patent/CN101633644B/zh not_active Expired - Lifetime
- 2003-12-12 BR BR122018007328A patent/BR122018007328B8/pt active IP Right Grant
-
2004
- 2004-09-09 IS IS7442A patent/IS2748B/is unknown
- 2004-09-09 IL IL163995A patent/IL163995A/en active IP Right Grant
-
2005
- 2005-02-18 US US11/061,336 patent/US7425637B2/en not_active Expired - Lifetime
- 2005-04-26 HK HK05103569.0A patent/HK1070823A1/xx not_active IP Right Cessation
-
2007
- 2007-10-09 JP JP2007263512A patent/JP2008019277A/ja active Pending
-
2008
- 2008-01-29 JP JP2008017547A patent/JP5102642B2/ja not_active Expired - Lifetime
- 2008-03-18 US US12/050,847 patent/US7576114B2/en not_active Expired - Lifetime
- 2008-03-18 US US12/050,827 patent/US7777050B2/en not_active Expired - Lifetime
-
2009
- 2009-10-07 AU AU2009222613A patent/AU2009222613B2/en active Active
-
2010
- 2010-01-13 CY CY20101100037T patent/CY1109727T1/el unknown
- 2010-03-10 IL IL204420A patent/IL204420A/en active Protection Beyond IP Right Term
- 2010-03-10 IL IL204419A patent/IL204419A/en active IP Right Grant
- 2010-06-09 HK HK10105717.9A patent/HK1141976A1/xx not_active IP Right Cessation
- 2010-06-28 US US12/824,521 patent/US8193229B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,497 patent/US7973170B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,559 patent/US8178693B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,547 patent/US8193230B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,477 patent/US8003805B2/en not_active Expired - Lifetime
- 2010-06-29 US US12/826,158 patent/US8193231B2/en not_active Expired - Lifetime
-
2011
- 2011-04-20 DO DO2011000109A patent/DOP2011000109A/es unknown
- 2011-04-20 DO DO2011000110A patent/DOP2011000110A/es unknown
- 2011-06-16 IS IS8961A patent/IS2999B/is unknown
- 2011-06-16 IS IS8960A patent/IS2998B/is unknown
- 2011-06-16 IS IS8959A patent/IS2990B/is unknown
- 2011-07-13 HK HK11107302.5A patent/HK1153139A1/zh not_active IP Right Cessation
-
2012
- 2012-05-03 US US13/463,487 patent/US8513293B2/en not_active Expired - Lifetime
- 2012-08-24 JP JP2012184708A patent/JP5498546B2/ja not_active Expired - Lifetime
- 2012-08-29 CL CL2012002380A patent/CL2012002380A1/es unknown
- 2012-08-29 CL CL2012002381A patent/CL2012002381A1/es unknown
-
2013
- 2013-01-28 DO DO2013000023A patent/DOP2013000023A/es unknown
- 2013-02-25 AR ARP130100568A patent/AR090144A2/es unknown
- 2013-02-25 AR ARP130100567A patent/AR090143A2/es unknown
-
2017
- 2017-07-27 CY CY20171100805T patent/CY1119136T1/el unknown
-
2019
- 2019-02-12 LU LU00100C patent/LUC00100I2/fr unknown
- 2019-03-01 HU HUS1900011C patent/HUS1900011I1/hu unknown
- 2019-03-07 LT LTPA2019007C patent/LTC1482932I2/lt unknown
- 2019-03-13 BE BE2019C510C patent/BE2019C510I2/fr unknown
- 2019-03-15 NL NL300974C patent/NL300974I2/nl unknown
- 2019-03-18 CY CY2019012C patent/CY2019012I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2130537T3 (da) | N3-alkylerede benzimidazolderivater som MEK-inhibitorer | |
DK1492785T3 (da) | 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer | |
CY2016042I1 (el) | Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων | |
NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
IS7667A (is) | Nýjar bensimídazólafleiður | |
IS8384A (is) | Alkýleraðar bensímídasólafleiður sem MEK-hindrar | |
DK1789041T3 (da) | Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer | |
NO20044654L (no) | Piperidinoylpiperidiner som 5-HTIF-agonister | |
DK1797042T3 (da) | Indozolonderivater som 11B-HSD1-inhibitorer | |
NO20052887D0 (no) | Pyridazinonderivater som GSK-3Beta inhibitorer. | |
DK1585749T3 (da) | Diazepinoindol-derivater som kinaseinhibitorer | |
NO20043793L (no) | Nikotinamidderivater anvendelige som PDE4 inhibitorer | |
NO20055680D0 (no) | Heksahydropyridoisokinoliner som DPP-IV-inhibitorer | |
DK1542977T3 (da) | 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12 | |
NO20051236L (no) | Heterobiarylderivater som matriksmetalloproteinaseinhibitorer | |
DK1740569T3 (da) | Imidazol-derivater som TAFla-inhibitorer | |
DE60320933D1 (de) | Rho-kinase inhibitoren | |
DK1603570T3 (da) | Aminoheteroarylforbindelser som proteinkinaseinhibitorer | |
ATE386518T1 (de) | Benzimidazolderivate | |
DK2039685T3 (da) | Heterobicycliske forbindelser som P38-inhibitorer | |
NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
DK1499316T3 (da) | (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister | |
NO20044998L (no) | Tioksantinderivater som myeloperoksidaseinhibitorer | |
DK1311488T3 (da) | Substituerede imidazoler som tafia-inhibitorer | |
DK1511718T3 (da) | N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer |